HER-2-negative breast cancer limitations and next-generation sequencing technology promises.
Baltogiannis
Georgios
G
Katsios
Christos
C
Zografos
George C
GC
Roukos
Dimitrios H
DH
D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D019718:Receptors, CXCR4 / Q000235:genetics; D017422:Sequence Analysis, DNA / Q000379:methods
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D019718:Receptors, CXCR4; C508053:ERBB2 protein, human